Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.46 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.46 |
| ▸ | GJA1 | P17302 | 1/20 | 0.45 |
| ▸ | GJB2 | P29033 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 3/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | IGF2R | P11717 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30489394 | 1.00 | L3MBTL1 (0.54) | L3MBTL1MEN1KMT2ALGALS8LGALS3 | |
| SCHEMBL14268486 | 1.00 | L3MBTL1 (0.54) | L3MBTL1MEN1KMT2ALGALS8LGALS3 | |
| SCHEMBL31530638 | 1.00 | L3MBTL1 (0.54) | L3MBTL1MEN1KMT2ALGALS8LGALS3 | |
| SCHEMBL3188633 | 0.81 | MEN1 (0.50) | L3MBTL1MEN1KMT2ALGALS8LGALS3 | |
| SCHEMBL6900928 | 0.81 | MEN1 (0.50) | L3MBTL1MEN1KMT2ALGALS8LGALS3 | |
| SCHEMBL1389240 | 0.81 | MEN1 (0.50) | L3MBTL1MEN1KMT2ALGALS8LGALS3 | |
| SCHEMBL2139671 | 0.81 | MEN1 (0.50) | L3MBTL1MEN1KMT2ALGALS8LGALS3 | |
| SCHEMBL2139680 | 0.81 | MEN1 (0.50) | L3MBTL1MEN1KMT2ALGALS8LGALS3 | |
| SCHEMBL9418205 | 0.79 | MEN1 (0.61) | L3MBTL1MEN1KMT2ALGALS8LGALS3 | |
| SCHEMBL9418216 | 0.79 | MEN1 (0.61) | L3MBTL1MEN1KMT2ALGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741511-A2 | METHODS AND COMPOSITIONS FOR ANALYZING CELLULAR COMPONENTS | ILLUMINA, INC. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260125670-A1 | ANALYSIS SYSTEM FOR ORTHOGONAL ACCESS TO AND TAGGING OF BIOMOLECULES IN CELLULAR COMPARTMENTS | ILLUMINA, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12618107-B2 | Methods for forming adapter ligated nucleic acid molecules | NEW ENGLAND BIOLABS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12595506-B2 | Compositions and methods for analyzing modified nucleotides | NEW ENGLAND BIOLABS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-3856920-B1 | 5' ADAPTER COMPRISING AN INTERNAL 5'-5' LINKAGE | REVVITY HEALTH SCIENCES INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12570971-B2 | Contiguity preserving transposition | ILLUMINA CAMBRIDGE LIMITED (GB) | 2026-03-10 | — | — | US | disclosed |
| US-20260049347-A1 | Real Time Cleavage Assay | EXACT SCIENCES CORP (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4308902-B1 | METHOD FOR LABEL-FREE CELL ACTIVATION PROFILING USING MICROFLUIDIC IMPEDANCE CYTOMETRY | UNIV NANYANG TECH (SG) | 2026-02-18 | — | — | EP | disclosed |
| EP-4677112-A2 | METHODS FOR ENRICHING AND DETECTING A TARGET POLYNUCLEOTIDE IN A SAMPLE | Nexgen Cancer Detection LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-3725893-B1 | COMPOSITIONS FOR ANALYZING CELLULAR COMPONENTS | ILLUMINA INC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-11339422-B2 | Methods of analyzing nucleic acids | ILLUMINA, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220152071-A1 | MARKERS OF EFFICACY OF TOPOISOMERASE POISONS | NORTHWESTERN UNIVERSITY | 2022-05-19 | — | — | US | disclosed |
| US-11326160-B2 | Method for making a cDNA library | BIOO SCIENTIFIC CORPORATION (US) | 2022-05-10 | — | — | US | disclosed |
| US-20220136035-A1 | NUCLEIC ACID CONTROL MOLECULES FROM NON-HUMAN ORGANISMS | JPMORGAN CHASE BANK, N.A. | 2022-05-05 | — | — | US | disclosed |
| US-20220117258-A1 | COMPOSITIONS COMPRISING A CASEIN AND METHODS OF PRODUCING THE SAME | Perfect Day, Inc. (US) | 2022-04-21 | — | — | US | disclosed |
| EP-3978618-A1 | ALBUMIN-BASED NON-COVALENT COMPLEXES AND METHODS OF USE THEREOF | Spectral Platforms, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3977862-A1 | COMPOSITIONS COMPRISING A CASEIN AND METHODS OF PRODUCING THE SAME | Perfect Day, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3645744-B1 | METHOD FOR REMOVING AND/OR DETECTING NUCLEIC ACIDS HAVING MISMATCHED NUCLEOTIDES | NEW ENGLAND BIOLABS INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11275088-B2 | BCR-ABL variants | QUEST DIAGNOSTICS INVESTMENTS LLC (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220033885-A1 | METHOD OF IDENTIFYING SEQUENCE VARIANTS USING CONCATENATION | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125670-A1 | ANALYSIS SYSTEM FOR ORTHOGONAL ACCESS TO AND TAGGING OF BIOMOLECULES IN CELLULAR COMPARTMENTS | TPR, IPO8, CTCF | L3MBTL1 267/4885MEN1 2323/4885KMT2A 850/4885 |
| US-12570971-B2 | Contiguity preserving transposition | DNMT3B, DNMT3A, DNMT1 | L3MBTL1 54/4885MEN1 3045/4885KMT2A 63/4885 |
| US-20220152071-A1 | MARKERS OF EFFICACY OF TOPOISOMERASE POISONS | DNASE1L3, RPLP1, RIOX2 | L3MBTL1 1808/4885MEN1 3291/4885KMT2A 4198/4885 |
| US-12618107-B2 | Methods for forming adapter ligated nucleic acid molecules | ADAR, LIG3, RNGTT | L3MBTL1 137/4885MEN1 4043/4885KMT2A 1636/4885 |
| US-20260049347-A1 | Real Time Cleavage Assay | FEN1, CASP14, CASP5 | L3MBTL1 1642/4885MEN1 4201/4885KMT2A 4272/4885 |
| US-12595506-B2 | Compositions and methods for analyzing modified nucleotides | UNG, RNMT, NT5C3B | L3MBTL1 841/4885MEN1 3198/4885KMT2A 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.